SAN DIEGO, June 20, 2017 /PRNewswire/ -- Dthera Sciences (OTC: DTHR), a San Diego-based digital therapeutics company working to improve quality of life (QoL) and reduce anxiety in patients with Alzheimer's disease and other forms of dementia, announced today that its chief executive officer, Edward Cox, will present at the Digital Health Summer Summit in San Diego.
The Digital Health Summer Summit takes place June 19-20 and offers programming around cutting-edge health and medical technologies, featuring speakers who are innovators, thought leaders and disrupters in digital health. The summit is co-located at the San Diego Convention Center with the 2017 BIO International Convention (BIO), the world's largest biotechnology convention, which is held June 17-22.
Mr. Cox will present as one of three companies on "Who's Dominating Digital Therapeutics?" which will take place on Tuesday, June 20th at 2:25 p.m. in Room 6EF.
"We are honored and excited to be presenting alongside such important innovators as Click Therapeutics and Neurotrack. They have long been market leaders in the digital therapeutics space, and we are excited to be part of the growing community raising awareness and importance for digital therapeutics," commented Mr. Cox. "It is particularly gratifying to be part of the program the year the event is being held here in San Diego, where our company is headquartered."
"The Digital Health Summer Summit is a destination for healthcare professionals who want to be on the cutting-edge of the innovation taking place in the medical and pharmaceutical industry," said Jill Gilbert, Producer, Digital Health Summer Summit. "We are thrilled to welcome Edward and Dthera Sciences to our stage to share the incredible strides they are making toward improving Quality of Life for Alzheimer's and Dementia patients by utilizing groundbreaking digital therapeutic technologies."
About Dthera Sciences:
Dthera Sciences (OTC:DTHR) is a publicly-traded digital therapeutics company based in San Diego, California focused on improving the quality of life of patients and their families. The Company's lead product, ReminX, is an artificial-intelligence-powered digital therapeutic designed to improve the quality of life (QoL) and reduce anxiety in patients with Alzheimer's disease and other forms of dementia. For more information please visit www.dthera.com
About Digital Therapeutics:
Digital Therapeutics is a new subsection of digital health that strives to directly deliver a therapy via use or interaction with software technology. The goal of Digital Therapeutics is to mirror an effective treatment and use technology to scale it to a larger patient population, thereby amplifying doctors' and nurses' care, changing patient behavior, and most importantly, reducing cost of care.
About Reminiscence Therapy:
Reminiscence Therapy involves discussing and reviewing recognizable memories, typically by looking at photos, and hearing or discussing the familiar stories related to them. It has been shown to be very effective at reducing anxiety and increasing the overall Quality of Life (QoL) in Alzheimer's and Dementia patients in numerous clinical trials and has been in use for nearly 30 years.
Dthera Sciences Forward-Looking Statement
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of medical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC's website at www.sec.gov or without charge from the Company.
For more information: Bret Shapiro, 561-479-8566, [email protected]
Advertisement
The Digital Health Summer Summit takes place June 19-20 and offers programming around cutting-edge health and medical technologies, featuring speakers who are innovators, thought leaders and disrupters in digital health. The summit is co-located at the San Diego Convention Center with the 2017 BIO International Convention (BIO), the world's largest biotechnology convention, which is held June 17-22.
Advertisement
Mr. Cox will present as one of three companies on "Who's Dominating Digital Therapeutics?" which will take place on Tuesday, June 20th at 2:25 p.m. in Room 6EF.
"We are honored and excited to be presenting alongside such important innovators as Click Therapeutics and Neurotrack. They have long been market leaders in the digital therapeutics space, and we are excited to be part of the growing community raising awareness and importance for digital therapeutics," commented Mr. Cox. "It is particularly gratifying to be part of the program the year the event is being held here in San Diego, where our company is headquartered."
"The Digital Health Summer Summit is a destination for healthcare professionals who want to be on the cutting-edge of the innovation taking place in the medical and pharmaceutical industry," said Jill Gilbert, Producer, Digital Health Summer Summit. "We are thrilled to welcome Edward and Dthera Sciences to our stage to share the incredible strides they are making toward improving Quality of Life for Alzheimer's and Dementia patients by utilizing groundbreaking digital therapeutic technologies."
About Dthera Sciences:
Dthera Sciences (OTC:DTHR) is a publicly-traded digital therapeutics company based in San Diego, California focused on improving the quality of life of patients and their families. The Company's lead product, ReminX, is an artificial-intelligence-powered digital therapeutic designed to improve the quality of life (QoL) and reduce anxiety in patients with Alzheimer's disease and other forms of dementia. For more information please visit www.dthera.com
About Digital Therapeutics:
Digital Therapeutics is a new subsection of digital health that strives to directly deliver a therapy via use or interaction with software technology. The goal of Digital Therapeutics is to mirror an effective treatment and use technology to scale it to a larger patient population, thereby amplifying doctors' and nurses' care, changing patient behavior, and most importantly, reducing cost of care.
About Reminiscence Therapy:
Reminiscence Therapy involves discussing and reviewing recognizable memories, typically by looking at photos, and hearing or discussing the familiar stories related to them. It has been shown to be very effective at reducing anxiety and increasing the overall Quality of Life (QoL) in Alzheimer's and Dementia patients in numerous clinical trials and has been in use for nearly 30 years.
Dthera Sciences Forward-Looking Statement
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of medical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC's website at www.sec.gov or without charge from the Company.
For more information: Bret Shapiro, 561-479-8566, [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/digital-therapeutics-leader-dthera-sciences-ceo-takes-the-stage-at-2017-digital-health-summer-summit-in-san-diego-300476382.html
SOURCE Dthera Sciences
